+47 464 40 045
Jan A. Alfheim is a business executive with over thirty years’ experience bringing product ideas and technology to the chemical and pharmaceutical markets, from product concept inception through discovery and development phases to final marketing campaign and launch.
With experience in research, project management, business development & partnering, company start-ups, and product launches, Alfheim comes from Nordic Nanovector ASA where he was Chief Executive Officer from 2011 until 2014 and Chief Operating Officer from 2014 to 2016. Prior to working at Nordic Nanovector, he has held various senior roles including Chief Business Officer at Clavis Pharma, President of StemPath Inc, Director of Business Development at Neurochem Inc and Project Director at Nycomed Imaging. Mr. Alfheim holds a MSc from Concordia University and a MBA from McGill University.
+47 470 24 922
Dr. Tina B. Bønsdorff has more than 15 years of research experience in molecular biology. She has a Ph.D. and postdoctoral experience from the Norwegian School of Veterinary Science, where she worked in the field of gene identification, expression and mutation analysis. Her postdoctoral research was focused on gene expression analysis of early neoplastic lesions in dog with inherited cancer syndromes. Dr. Bønsdorff is one of the founders of Oncoinvent AS. Dr. Bønsdorff has been the Chief Scientific Officer of Oncoinvent AS from the start-up, and was the CEO of the company from August 2013 to September 2016.
Dr. Øyvind S. Bruland is a MD, Ph.D. and professor of Clinical Oncology with the Faculty of Medicine, University of Oslo and senior consultant oncologist at the Dept. of Oncology, Oslo University Hospital and has supervised a large number of Ph.D. students in this capacity. He founded Algeta ASA in 1997 together with Dr. Roy H. Larsen, and he was one of the founders of Nordic Nanovector ASA (2009) and of Oncoinvent AS (2010). Øyvind S. Bruland served as a member of the board of Oncoinvent AS from 2010 to 2016. Professor Bruland’s main clinical experience and research has been devoted to primary bone and soft tissue cancers (sarcomas).
+47 959 34 199
+47 932 06 611
Kristine Lofthus has more than 15 years experience with the manufacturing of pharmaceuticals. Her main field of expertise is the manufacturing of aseptic and terminally sterilized injectables, and in particular radiopharmaceuticals. This experience includes production and production management, quality assurance and the certification and release of batches as a Qualified Person. Kristine holds a cand. pharm. degree (M.Sc.) from the University of Oslo, a certificate of Advanced Studies (CAS) in Radiopharmaceutical Chemistry/Radiopharmacy from Eidgenössische Technische Hochschule Zürich and is a licensed Qualified Person at Oncoinvent AS
+47 906 99 816
Kari Skinnemoen has more than 35 years’ experience in the pharmaceutical and medical device industries within global regulatory affairs, quality assurance, quality control and research and development. This experience includes management and project management positions within the development of contrast media (Nycomed Imaging now GE Healthcare), photodynamic therapy of skin cancers (Photocure) and in-vitro diagnostic products (Alere Technologies). She is licensed as Qualified Person for batch release at Oncoinvent. Kari holds a cand. real. degree (M.Sc.) from University in Oslo in chemistry, mathematics and biology with a thesis in organic chemistry.
Anne-Kirsti Aksnes, PhD has >25 years of clinical development experience, in pharmaceuticals and radiopharmaceuticals, former VP Clinical of Algeta, and VP Clinical of Targovax. (She will start in Oncoinvent 1. August 2021)
+47 971 24 060
Dr. Hans M. Hild has more than 15 years’ experience in the GMP compliant production of sterile- and aseptically produced pharmaceuticals and radiopharmaceuticals. He previously has worked for the Institute for Energy Technology, GE Healthcare, Avecia Biotechnology (formerly Zeneca LSM Ltd.) and Degussa AG, and has a strong background in pharmaceutical process development, scale-up and technology transfer. He has extensive experience in the production of biopharmaceuticals and contrast media for early clinical studies, as well as experience in the commercial production of radiopharmaceuticals. Dr. Hild holds an Dipl. Ing. (FH) degree in Chemical Engineering from FH Frankfurt am Main, an M.Sc. in Biochemical Engineering from the University of Birmingham and a Ph.D. in Biochemical Engineering from Imperial College London.
+47 979 83 092
Gro Hjellum has more than 25 years of experience within research & development and operations in the pharmaceutical and biotech industry, ranging from analytical sciences, quality control and bio-analysis from preclinical product development through to regulatory approval of products. Prior to joining Oncoinvent, Gro worked for Nycomed/GE-Healthcare and Algeta/Bayer. She has a strong background in radiopharmaceutical product development and technology transfer to contract manufacturers in Norway as well as to US and Japan. Ms. Hjellum holds an MSc degree in radiochemistry from the University of Oslo.